Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|August 21, 2018
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hitHui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, et al.Chemmedchem|December 7, 2018
Discovery of Affinity-Based Probes for Btk Occupancy AssaysHui Qiu, Richard Caldwell, Lesley Liu-Bujalski, et al.Bioorganic & Medicinal Chemistry Letters|September 24, 2018
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitorsHui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, et al.Chemmedchem|September 28, 2021
Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory ActivityHui Qiu, Zahid Ali, Julian Bowlan, et al.Bioorganic & Medicinal Chemistry Letters|July 13, 2010
Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitorsHu Liu, Cyrille Kuhn, Frederic Feru, et al.Scientific Reports|July 31, 2020
Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agentJoseph A Reddy, Melissa Nelson, Christina Dircksen, et al.Journal of Medicinal Chemistry|October 1, 2021
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered CancersLizbeth DeSelm, Bayard Huck, Ruoxi Lan, et al.Bioorganic & Medicinal Chemistry Letters|September 5, 2021
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitorsYufang Xiao, Bayard R Huck, Ruoxi Lan, et al.Bioorganic & Medicinal Chemistry|May 1, 2021
Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitorsHui Qiu, Zahid Ali, Andrew Bender, et al.Bioorganic & Medicinal Chemistry|August 2, 2023
Discovery of quinazoline HPK1 inhibitors with high cellular potencyMomar Toure, Theresa Johnson, Bin Li, et al.Pageof 3